Celgene (NASDAQ:CELG) has been given a $128.00 price objective by equities researchers at Mizuho in a research report issued to clients and investors on Tuesday. The brokerage currently has a “buy” rating on the biopharmaceutical company’s stock. Mizuho’s target price indicates a potential upside of 22.53% from the stock’s previous close.
A number of other equities analysts have also recently issued reports on CELG. Cantor Fitzgerald reissued a “buy” rating on shares of Celgene in a report on Monday, August 28th. Vetr cut Celgene from a “strong-buy” rating to a “buy” rating and set a $146.88 target price for the company. in a report on Tuesday, August 29th. BTIG Research reissued a “neutral” rating on shares of Celgene in a report on Tuesday, September 5th. Cowen reissued a “buy” rating and issued a $150.00 target price on shares of Celgene in a report on Tuesday, September 12th. Finally, Bank of America reissued a “buy” rating on shares of Celgene in a report on Wednesday, September 13th. Two analysts have rated the stock with a sell rating, twelve have assigned a hold rating, twenty have assigned a buy rating and one has issued a strong buy rating to the stock. The stock has a consensus rating of “Buy” and an average price target of $133.95.
Celgene (NASDAQ CELG) traded down $2.51 during trading on Tuesday, reaching $104.46. The company’s stock had a trading volume of 4,749,297 shares, compared to its average volume of 4,822,178. The company has a debt-to-equity ratio of 1.31, a quick ratio of 3.52 and a current ratio of 3.65. The firm has a market cap of $83,720.00, a PE ratio of 24.64, a price-to-earnings-growth ratio of 0.82 and a beta of 1.77. Celgene has a 12-month low of $94.55 and a 12-month high of $147.17.
A number of institutional investors have recently modified their holdings of the stock. Nationwide Fund Advisors boosted its holdings in shares of Celgene by 38.5% during the fourth quarter. Nationwide Fund Advisors now owns 885,689 shares of the biopharmaceutical company’s stock worth $106,070,000 after acquiring an additional 246,194 shares during the period. Ngam Advisors L.P. raised its position in shares of Celgene by 3.6% in the second quarter. Ngam Advisors L.P. now owns 166,196 shares of the biopharmaceutical company’s stock valued at $16,392,000 after buying an additional 5,707 shares in the last quarter. SG Americas Securities LLC raised its position in shares of Celgene by 175.9% in the third quarter. SG Americas Securities LLC now owns 91,485 shares of the biopharmaceutical company’s stock valued at $9,563,000 after buying an additional 212,007 shares in the last quarter. Jennison Associates raised its position in shares of Celgene by 28.3% in the third quarter. Jennison Associates now owns 12,365,141 shares of the biopharmaceutical company’s stock valued at $1,337,537,000 after buying an additional 2,728,714 shares in the last quarter. Finally, PICTET BANK & TRUST Ltd raised its position in shares of Celgene by 16.5% in the third quarter. PICTET BANK & TRUST Ltd now owns 35,445 shares of the biopharmaceutical company’s stock valued at $3,705,000 after buying an additional 5,025 shares in the last quarter. 79.74% of the stock is currently owned by institutional investors and hedge funds.
About Celgene
Celgene Corporation is an integrated global biopharmaceutical company. The Company, together with its subsidiaries, is engaged in the discovery, development and commercialization of therapies for the treatment of cancer and inflammatory diseases through solutions in protein homeostasis, immuno-oncology, epigenetics, immunology and neuro-inflammation.
